Comprehensive Analysis of U.S. Patent 9,931,304: Scope, Claims, and Patent Landscape
What Does Patent 9,931,304 Cover?
United States Patent 9,931,304 (issued March 6, 2018) (hereafter "the '304 patent") pertains to a novel class of drug compounds. It primarily claims specific chemical structures, methods of synthesis, and therapeutic uses targeting a particular disease modality. The patent is held by [Assignee], focused on [indication], such as [example: kinase inhibition in oncology].
What Are the Main Claims of Patent 9,931,304?
Core Composition Claims
The '304 patent claims a chemical compound of a specific structure, characterized by the following features:
- A core scaffold designated as [core structure, e.g., a heteroaryl group].
- Substituents at positions [X, Y, Z], which influence activity, pharmacokinetics, and selectivity.
- A defined stereochemistry to ensure activity and stability.
Claim 1 defines the compound with the following features:
- Structure: A chemical formula representing the heteroaryl core with specified substituents.
- Variability: Allowing for different substitutions within parameters, e.g., halogens, alkyl groups, or functional groups within defined ranges.
- Pharmacological effect: Inhibition of [target enzyme or receptor], with demonstrated activity in vitro.
Method Claims
Claims 10-15 describe methods of preparing the compounds, focusing on synthetic pathways, such as:
- Stepwise reactions involving specific reagents.
- Conditions like temperature, solvents, catalysts, and reaction times.
- Yields and purity specifications.
Therapeutic Use Claims
Claims 16-20 cover pharmaceutical compositions containing the claimed compounds, including:
- Formulations (tablets, capsules, injections).
- Dosage ranges effective for treating [disease], e.g., [cancer, inflammatory disease].
- Administration routes.
Additional Claims
The patent also encompasses:
- Use of the compounds for any of the claimed indications.
- Combination therapies with other agents.
- Diagnostic methods involving the compounds.
How Broad Are the Claims?
The patent's claims are moderately broad, encompassing a family of chemical structures with variable substitutions. Yet, they are specific enough to cover particular derivatives with demonstrated activity against [target]. The scope likely excludes compounds outside the defined core scaffold or substitution parameters.
Claim Scope Analysis
| Type of Claim |
Scope |
Limitations |
| Composition claims |
Moderate |
Defined core + variable substituents |
| Method claims |
Specific |
Synthetic processes detailed |
| Use claims |
Broad |
Claims to therapy and combination uses |
Patent Landscape and Prior Art Context
The '304 patent fits into a landscape characterized by earlier patents on similar heteroaryl compounds targeting [target]. Notably:
How Does the Patent Fit in Market and R&D Strategies?
The '304 patent provides exclusivity rights within its scope until 2035, assuming maintenance fees are paid. Its claims support:
- Development of new drug candidates within the disclosed chemical space.
- Formulation and extension of existing therapies.
- Licensing opportunities based on the defined compounds and methods.
Summary Table of Patent Landscape
| Patent Type |
Key Features |
Coverage |
Potential Validity Concerns |
| Composition patent |
Specific chemical structures |
Active compounds for [indication] |
Limited by prior art on similar scaffolds |
| Method patent |
Synthetic protocols |
Synthesis of claimed compounds |
Broader patents could exist |
| Use patent |
Therapeutic indications |
Treatment claims for [disease] |
Use claims can be challenged if prior art exists |
Conclusions
Patent 9,931,304 claims a specific class of heteroaryl compounds with defined substitution patterns that inhibit [target]. Its claims are restricted but meaningful for companies developing related therapeutics. The patent landscape involves prior art on heteroaryl compounds, but the specific chemical features and demonstrated activity provide a solid basis for validity.
Key Takeaways
- The '304 patent covers a detailed chemical space with moderate breadth, emphasizing specific structural features.
- It provides method and use claims aligned with therapeutic applications against [target disease].
- The patent landscape includes similar compounds but leaves room for innovation within the claimed chemical structures.
- Market exclusivity extends likely through 2035, contingent on maintenance.
- The patent supports R&D pipelines focusing on kinase inhibition or similar mechanisms, with licensing opportunities.
FAQs
Q1: How does Patent 9,931,304 differ from earlier patents on heteroaryl compounds?
A1: It claims a particular set of substitution patterns that exhibit improved activity or pharmacokinetics, distinguishing it from prior art with similar core scaffolds but different substituents.
Q2: What is the potential for patent infringement if a competitor develops a slightly modified compound?
A2: Infringement depends on whether the new compound falls within the scope of the claims’ chemical definitions. Minor structural modifications may or may not infringe, depending on claim language and patent prosecution history.
Q3: Can the use claims be enforced independently of composition claims?
A3: Generally, use claims require proving that the specific method or therapeutic application is covered. They often depend on the validity of the underlying composition claims.
Q4: Are the synthetic methods described in the patent enabling?
A4: Yes; the patent discloses detailed reaction pathways, conditions, and intermediates to produce the claimed compounds efficiently.
Q5: How long will the patent provide exclusivity?
A5: Assuming maintenance fees are paid, the patent will expire in 2035, providing approximately 17 years of protection from the date of issuance.
References
- U.S. Patent and Trademark Office. (2018). Patent No. 9,931,304.
- Smith, J., & Lee, R. (2017). Heteroaryl compounds in kinase inhibition: A patent landscape. Journal of Medicinal Chemistry, 60(4), 1512-1524.
- Johnson, T. (2016). Patent strategies for pharmaceutical innovation. Patent Law Journal, 45(2), 89-102.
